PMID- 18295671
OWN - NLM
STAT- MEDLINE
DCOM- 20080403
LR  - 20111117
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 69
IP  - 1
DP  - 2008 Jan
TI  - Human leukocyte antigen-G1 inhibits natural killer cytotoxicity through blocking 
      the activating signal transduction pathway and formation of activating 
      immunologic synapse.
PG  - 16-23
LID - 10.1016/j.humimm.2007.11.005 [doi]
AB  - Nonclassical major histocompatibility complex (MHC) class I molecule human 
      leukocyte antigen (HLA)-G is normally expressed on the placental cells, 
      especially fetal endothelial cells and invasive cytotrophoblast cells at the 
      maternal-fetal interface. This antigen meditates immune tolerance in pregnancy 
      through interaction with immune cells including natural killer (NK) cells. In 
      this study, we investigated the mechanisms underlying HLA-G1-mediated inhibition 
      of NK cytotoxicity using HLA-G1-transfected K562 cells and NK92 cells. We found 
      that inhibition of NK cytotoxicity by HLA-G1 was associated with decreased 
      formation of NK-target cell conjugates and defective formation of immunologic 
      synapse, as characterized by actin depolarization and perforin immobilization in 
      nonactive NK cells. HLA-G1 engagement induced dephosphorylation of Vav by 
      tyrosine phosphatase-1 (SHP-1), and thus blocked the Syk-->MEK/ERK activating 
      signaling pathway in activating NK cells. These results indicate that HLA-G1 
      inhibits NK cytotoxicity by blocking activating signal transduction pathway, 
      which is required for the formation of activating immunologic synapse.
FAU - Yu, Yanrong
AU  - Yu Y
AD  - State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of 
      Zoology, Chinese Academy of Sciences, Beijing, People's Republic of China.
FAU - Wang, Yun
AU  - Wang Y
FAU - Feng, Meifu
AU  - Feng M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071226
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Proto-Oncogene Proteins c-vav)
RN  - EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 6)
SB  - IM
MH  - Actin Cytoskeleton/ultrastructure
MH  - Cell Line
MH  - *Cytotoxicity, Immunologic
MH  - HLA Antigens/*metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - K562 Cells
MH  - Killer Cells, Natural/enzymology/*immunology/ultrastructure
MH  - *MAP Kinase Signaling System
MH  - Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism
MH  - Proto-Oncogene Proteins c-vav/metabolism
EDAT- 2008/02/26 09:00
MHDA- 2008/04/04 09:00
CRDT- 2008/02/26 09:00
PHST- 2007/08/10 00:00 [received]
PHST- 2007/11/05 00:00 [revised]
PHST- 2007/11/13 00:00 [accepted]
PHST- 2008/02/26 09:00 [pubmed]
PHST- 2008/04/04 09:00 [medline]
PHST- 2008/02/26 09:00 [entrez]
AID - S0198-8859(07)00469-7 [pii]
AID - 10.1016/j.humimm.2007.11.005 [doi]
PST - ppublish
SO  - Hum Immunol. 2008 Jan;69(1):16-23. doi: 10.1016/j.humimm.2007.11.005. Epub 2007 
      Dec 26.